A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir; Lamivudine
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms Gemini 1
- Sponsors ViiV Healthcare
- 10 Jun 2017 Biomarkers information updated
- 10 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.